Going direct: notes on Eli Lilly at a trillion | Alex’s blog
Personal site for posts about my interests: the biotech industry, medicine, molecular biology, neuroscience, biorisk, science, consciousness, AI, innovation, decision making, philosophy, games, sci-fi, probability, and forecasting (among other things). I write to learn, mostly about biotech.
A few weeks ago, Eli Lilly CEO Dave Ricks appeared on Stripe’s “Cheeky Pint” podcast . It’s rare 1 for pharma executives to make unscripted media appearances (the industry is risk averse by nature), so seeing one sit down with the Collison brothers — on a tech podcast, no less — is notable. Pharma’s deliberate distance 2 has come at a cost: the industry has mostly failed to establish positive relationships with consumers. Tech, by contrast, consistently ranks as one of the most liked industries; pharma is one of the most disliked . Tech CEOs are household names, yet hardly anyone outside the i
Explore this link on the map →related reading
- Stratechery by Ben Thompson – On the business, strategy, and impact of technology.stratechery.com
- The Ozempocalypse Is Nigh - by Scott Alexanderastralcodexten.com
- Laws of Tech: Commoditize Your Complement · Gwern.netgwern.net
- Corporate Ozempic. If you want to understand how AI is… | by Scott Galloway | Mediummedium.com
- Pharma Virumque | Slate Star Codexslatestarcodex.com
- Some questions about biotech that I find interesting | Alex’s blogatelfo.github.io
- The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about it | Alex’s blogatelfo.github.io
- Going Founder Mode On Cancer - by Elliot Hershbergcenturyofbio.com
- Blog Feed – Kinetic Energy Ventures12mv2.com
- 2,851 Miles // Bill Gurley (Transcript + Slides) – Kinetic Energy Ventures12mv2.com
- The real winner of the Ozempic craze? Big Pharma | Dazeddazeddigital.com
- Where are all the trillion dollar biotechs?ladanuzhna.xyz